Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019

WOBURN, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that pre-clinical data on its oncolytic immunotherapy platform will be presented at a poster session today at the American Association for Cancer Research (AACR) Annual Meeting 2019 being held in Atlanta, Georgia.

“The pre-clinical data to be presented in this poster reiterates the ability of our platform to provide a potent and versatile approach to developing new therapies intended to maximally activate a patient’s immune system against their own cancer,” commented Robert Coffin, Ph.D., co-founder, President and CEO of Replimune. “This data supports the clinical development of our advancing pipeline of oncolytic immunotherapies, including our lead product candidate, RP1, and RP2 which additionally encodes an anti-CTLA-4 antibody.”

Details of Replimune’s poster presentation:

Abstract Title: Development & characterization of a new oncolytic immunotherapy platform based on herpes simplex virus type 1 (Abstract #3136)

Session Date and Time: Monday April 1, 2019, 8:00AM – 12:00PM

Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 22

The poster will be made available on the company’s website from the time of presentation.

Abstracts and full session details can be found at www.aacr.org

About Replimune

Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of “oncolytic immune-gene therapies” for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about our use of cash, our advancement of our clinical trials, our goals to develop and commercialize our product candidates, our plans to establish our own in-house manufacturing capabilities, our proposed scientific presentations, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of establishing, equipping, and operating our planned in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, and other risks set forth under the heading “Risk Factors” of our Quarterly Report on Form 10-Q for the third quarter ended December 31, 2018. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Replimune Contact
Pamela Esposito, Ph.D.
Replimune Group Inc.
617.233.6988
[email protected]

Investor Inquiries
Chris Brinzey
Westwicke Partners
339.970.2843
[email protected]

Media Inquiries
Arleen Goldenberg
Verge Scientific Communications
917.548.1582
[email protected]